122 related articles for article (PubMed ID: 24947092)
21. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer.
Hayashi M; Yamamoto Y; Ibusuki M; Fujiwara S; Yamamoto S; Tomita S; Nakano M; Murakami K; Iyama K; Iwase H
Ann Surg Oncol; 2012 Sep; 19(9):3042-9. PubMed ID: 22476757
[TBL] [Abstract][Full Text] [Related]
22. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
[TBL] [Abstract][Full Text] [Related]
23. Predicting breast cancer response to neoadjuvant chemotherapy using pretreatment diffuse optical spectroscopic texture analysis.
Tran WT; Gangeh MJ; Sannachi L; Chin L; Watkins E; Bruni SG; Rastegar RF; Curpen B; Trudeau M; Gandhi S; Yaffe M; Slodkowska E; Childs C; Sadeghi-Naini A; Czarnota GJ
Br J Cancer; 2017 May; 116(10):1329-1339. PubMed ID: 28419079
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
[TBL] [Abstract][Full Text] [Related]
25. [Comparison of response evaluation methods of neoadjuvant chemotherapy in breast cancer patients].
Sun B; Song ST; Wu SK; Jiang ZF; Wang T; Zhang SH; Zhao YB; Yu CZ; Li XB; Yang T; Li GJ
Zhonghua Zhong Liu Za Zhi; 2009 Oct; 31(10):783-5. PubMed ID: 20021835
[TBL] [Abstract][Full Text] [Related]
26. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathological features of breast cancer associated with the pathological complete response to anthracycline-based neoadjuvant chemotherapy.
Keskin S; Muslumanoglu M; Saip P; Karanlık H; Guveli M; Pehlivan E; Aydoğan F; Eralp Y; Aydıner A; Yavuz E; Ozmen V; Igci A; Topuz E
Oncology; 2011; 81(1):30-8. PubMed ID: 21912195
[TBL] [Abstract][Full Text] [Related]
28. Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer.
Ko ES; Han BK; Kim RB; Ko EY; Shin JH; Hahn SY; Nam SJ; Lee JE; Lee SK; Im YH; Park YH
Ann Surg Oncol; 2013 Aug; 20(8):2562-8. PubMed ID: 23463090
[TBL] [Abstract][Full Text] [Related]
29. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
30. [Predictive value of (99)Tc(m)-MIBI scintimammography in evaluation of the efficacy of neoadjuvant chemotherapy in patients with operable breast cancer].
Liu ZZ; Lu ZD; Zhang HW; Yang H; Liu H; Li LF; Li WL; Cui SD
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):544-6. PubMed ID: 22093636
[TBL] [Abstract][Full Text] [Related]
31. Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.
Parekh T; Dodwell D; Sharma N; Shaaban AM
Pathobiology; 2015 Sep; 82(3-4):124-32. PubMed ID: 26330353
[TBL] [Abstract][Full Text] [Related]
32. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
33. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
[TBL] [Abstract][Full Text] [Related]
34. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant chemotherapy: early response as a guide for further treatment: clinical, radiological, and biological.
Untch M; von Minckwitz G
J Natl Cancer Inst Monogr; 2011; 2011(43):138-41. PubMed ID: 22043061
[TBL] [Abstract][Full Text] [Related]
36. Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation.
Vinnicombe SJ; MacVicar AD; Guy RL; Sloane JP; Powles TJ; Knee G; Husband JE
Radiology; 1996 Feb; 198(2):333-40. PubMed ID: 8596827
[TBL] [Abstract][Full Text] [Related]
37. Proliferation rate and breast cancer subtype, but not ALDH1 expression, predict pathological response to neoadjuvant chemotherapy in locally advanced breast cancer.
Chatterjee D; Bal A; Das A; Singh G
Virchows Arch; 2015 Sep; 467(3):303-10. PubMed ID: 26063415
[TBL] [Abstract][Full Text] [Related]
38. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.
Cho N; Im SA; Park IA; Lee KH; Li M; Han W; Noh DY; Moon WK
Radiology; 2014 Aug; 272(2):385-96. PubMed ID: 24738612
[TBL] [Abstract][Full Text] [Related]
39. Impact of neoadjuvant chemotherapy on pathologic axillary nodal status in HER-2 positive patients presenting with clinically node-negative disease.
Al-Hilli Z; Hieken TJ; Hoskin TL; Heins CN; Boughey JC
J Surg Oncol; 2015 Oct; 112(5):453-7. PubMed ID: 26345596
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
